February 23, 2020
Brisbane, Australia-based public company ResApp, which creates smartphone apps for the diagnosis and management of respiratory diseases, announced last week that it has received firm commitments from institutional and sophisticated investors to raise $5 million.
The funds raised will be used to accelerate European commercialization and for general working capital. The placement received strong...
May 9, 2017
International medical organization Doctors Without Borders (Médecins sans Frontières, or MSF) is looking to evaluate the use of an app to diagnose and manage respiratory disease in rural, low-income settings. An unofficial collaboration is already in the works with Australian digital health company ResApp, whom MSF has indicated they are interested in working with in a clinical study.
October 24, 2016
ResApp, an Australian company developing an app to diagnose respiratory conditions based on cough sounds, has secured the first of three IRB approvals for its upcoming Smartcough-C pediatric trial, which will take place at the Cleveland Clinic, Massachusetts General Hospital, and a third site yet to be announced.
ResApp’s offering — an app called ResAppDx — essentially uses the smartphone...